This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Maclean, D. Articles by Maclean, D. Search for Related Content PubMed PubMed Citation Articles by Maclean, D. Articles by Maclean, D. Social Bookmarking                         What's this?

Bevantolol vs Propranolol: A Double-Blind Controlled Trial in Essential Hypertension

Derek Maclean

Clinical Pharmacology Ninewells Hospital & Medical School Dundee DDI 9SY, Scotland

Bevantolol is a novel ß ₁-selective beta-adrenoceptor antagonist. The Study Group evaluated its therapeutic utility (100-300 mg bid) compared with pro pranolol (80-240 mg bid) in 266 patients with mild to moderate essential hyper tension (WHO Grades I and II, sitting diastolic blood pressure (DBP) 95 mmHg). There was no difference in their antihypertensive efficacy over six months, 77% being controlled (DBP 90 mmHg) on bevantolol and 81 % on propranolol. Hydrochlorothiazide 25-50 mg bid added later improved BP con trol in those incompletely controlled on bevantolol monotherapy. Both ß- adrenoceptor antagonists also reduced intraocular pressure. Bevantolol caused significantly fewer adverse effects than propranolol with many fewer with drawals during long-term therapy. This unique clinical pharmacologic profile of bevantolol enhances its therapeutic usefulness and may relate to alpha-adreno ceptor antagonist activity, as well as to its ß₁-selectivity.

Angiology, Vol. 39, No. 6, 487-496 (1988)
DOI: 10.1177/000331978803900601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?